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ABSTRACT

CHARACTERIZATION OF AND NYC EXPRESSION IN A HL-60 MUTANT
RESISTANT TO DMSO INDUCED DIFFERENTIATION
Walter Michael Stadler
1988

The promyelocytic cell line, HL-60, has been extensively
studied for its ability to terminally differentiate in res¬
ponse to various chemical inducers, including, but not li¬
mited to, DMSO and retinoic acid.
It has also been noted
that the myc oncogene is amplified and highly expressed in
these cells.
Furthermore, differentiation in this line, as
well as in several other cell lines, is accompanied by a
marked decline in myc expression, leading to the hypothesis
that this decline is mechanistically important for differen¬
tiation to occur.
To probe this phenomenon more closely and
to test this hypothesis I isolated an HL-60 mutant that no
longer responded to DMSO induced differentiation and measured
myc expression in these cells following exposure to DMSO,
retinoic acid, or a combination of the two.
I show that such
a mutant is also partially cross resistant to retinoic acid
induced differentiation, that the myc gene locus is not
rearranged or changed in amplification status, and that a
decline in myc expression can be associated with an undif¬
ferentiated, replicating phenotype.
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ABBREVIATIONS
A26 0, A280:

absorbence of a s lution at 260 or 280 nm,
spectively

re-

DMSO

:

dimethyl sulfoxid

HMBA

:

N,N-hexamethylene bisacetamide

MOPS

:

buffer consisting of 20 mM morpholinopropanesulfonic acid, 5 mM
odium acetate and 1 mM EDTA
(pH 7.0)

NBT

:

nitroblue tetrazolium

NP40

:

octylphenol ethylene oxide condensate,
detergent

PBS

:

phosphate buffered saline

RA

:

all trans retinoic acid

SDS

:

sodium dodecyl

SSC

:

buffer consisting of 150 mM NaCl,
citrate (pH 7.0)

TE

:

buffer consisting of 10 mM Tris-HCl,
Number following is pH

TPA

:

12-O-tetradecanoylphorbol-l3-acetate

sulfate,

a nonionic

an ionic detergent
15 mM sodium

1 mM EDTA
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INTRODUCTION
The HL-60 cell line was originally isolated from a
patient with acute promyelocytic leukemia

(1,2).

It has been

shown that a variety of agents can induce these cells to
differentiate along either the granulocytic,
even eosinophilic pathways

(3-15).

monocytic,

or

The morphological matura¬

tion is accompanied by numerous functional and cytochemical
changes,
NET,

including the acquisition of the ability to reduce

an assay for the ability of phagocytic cells to generate

an oxidative burst

(4).

Although most of these changes

approximate the characteristics of normal granulocytes or
macrophages,

it has been pointed out that there are signifi¬

cant differences

(16,17).

Of particular note is the ability

of uninduced HL-60 cells to divide continuously in culture,
an unusual characteristic even of most leukemias,
grossly abnormal karyotype

and their

(2), which does not correspond to

any commonly recognized association between karyotype and
malignancy (18).
Yet,

like normal terminally differentiated cells,

in¬

duced HL-60 cells have a finite lifetime and cannot be main¬
tained in culture or cloned

(19).

It is for this reason,

that they are believed to be a good model system to investi¬
gate differentiation mechanisms and to explore differentia¬
tion induction as a possible therapeutic modality.
Oncogenes were first isolated from transforming retro¬
viruses

(20)

and subsequently from NIH3T3 cells transfected

%
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with tumor DNA (21).

They have since been identified in

normal cells and their elevated expression or mutated forms
identified in numerous human and animal malignancies

(22-26).

Oncogenes are thought to be involved in regulating growth and
replication.

In fact,

several have been shown to be growth

factors or growth factor
product of others,

receptors

(27-32).

such as the myc oncogene,

The protein
have also been

shown to reside in the nucleus and to bind double stranded
DNA (33).

Since a cardinal manifestation of a malignant cell

is an undifferentiated phenotype,

a role for some oncogenes

in maintaining such a state or in initiating the differen¬
tiated state was soon hypothesized and explored.

One of the

first such investigations used the HL-60 leukemia and showed
that during differentiation the RNA expression of the myc
oncogene was greatly reduced

(34).

It had already been shown

that the myc gene locus is amplified in these cells
Subsequent work showed changes in other oncogenes,

(35,36).
including

a similar decline in the expression of another nuclear onco¬
gene,

myb

(37),

and extended these observations to other

differentiating cell lines
In further studies,

(38-40).

the kinetics of the decline in myc

expression were more carefully defined

(19,41),

demonstrating

that they are mostly due to a specific decline in the myc
transcription rate

(42).

The decrease in expression is also

accompanied by a slight change in SI nuclease sensitive sites
of the myc gene

(43).

Finally,

constitutive expression of

4

myc in a mouse erythroleukemia line inhibited DMSO or HMBA
induced differentiation (44-46),

but transgenic mice with a

similarily activated myc locus developed normally (47,48).
Thus,

although it seemed that high myc levels were sufficient

to maintain the undifferentiated replicating phenotype,

there

was no direct information as to whether high levels of ex¬
pression were necessary.
To analyze the importance of myc expression to the
differentiation process,

I developed a mutant HL-60 line

which no longer responded to DMSO induced differentiation and
measured the effects of DMSO exposure on myc expression.
Several other investigators have
resistant HL-60 cells

(49-52).

reported isolating DMSO
One

report documented cross¬

resistance to several other

inducers,

in the myc gene copy number

(51).

as well as a reduction

Accompaning changes in the

expression of several cell membrane proteins were also noted,
but myc RNA expression was not measured

(53).

Another

report

showed a slight decline in myc expression in a DMSO resistant
mutant,

but the decrease was only 2-fold and only dot-blots

were used to document the finding

(52).

Here I

report a

marked decline in myc RNA expression following DMSO exposure
in mutant HL-60 cells unable to respond to DMSO induced
differentiation.

•
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METHODS

CELL CULTURE
HL-60 cells were originally obtained from Dr.
Gallo of the National Cancer Institute

(1)

Robert C.

and stock cultures

were maintained and stored at our facilities.

Cells were

grown in RPMI 1640 supplemented with 10% heat inactivated
fetal bovine serum,

100 units/ml penicillin,

and 100 ug

streptomycin at 37°C in a 5% CO2 humidified incubator.

They

were kept in exponential phase by splitting every 2-3 days
and were periodically tested to insure freedom from mycoplas¬
ma infection.

Every set of experiments was conducted by

growing a sufficient number of cells such that all

treatments

and time points were begun concurrently and with the same set
of seed cultures.

All media were prewarmed to 37°C.

The mutant cells were isolated as described in the
Results section and were maintained in the manner described
above except that the medium was also supplemented with 1.2%
DMSO.

Before beginning an experiment,

cells were washed in

drug-free medium and passaged once in drug-free medium before
resuspending in the appropriate treatment flasks.

All cell

counts were obtained on a Coulter model ZBI particle counter.

NBT TEST AND STAINING
To measure differentiation,
acid-washed slides,

fixed,

cells were cytospun onto

and stained for morphological

-

6

evaluation by a rapid staining solution (Canko Quik Stain II)
that approximates the Wright-Giemsa stain.
conducted as previously described

(4).

The NBT test was

One x 10

6

cells were

resuspended in 0.5 ml of medium and 0.5 ml of 0.2% NBT (made
up in sterile PBS protected from light,

and stored at 5°C).

TPA (from a 1 mM stock solution made up in DMSO,
from light,

protected

and stored at -20°C) was added to a final concen¬

tration of 0.1 uM and the suspension incubated at 37°C for 20
min.
ice,

The reaction was stopped by placing the solution on
the cells were collected by centrifugation,

in a minimal amount of medium,

resuspended

and the percentage of cells

containing black formazan particles was measured using a
standard counting chamber.

All cell counts

logy and NBT reduction) were done blindly,
cate,

(for both morpho¬
in at least dupli¬

and at least 200 cells were counted each time.

NORTHERN ANALYSIS
RNA was isolated by the guanidine thiocyanate method
(54)

and analysed by Northern blotting

(55,56).

Briefly,

cells collected by centrifugation were washed in ice-cold
PBS,

and resuspended in 0.7 ml of 4 M guanidine thiocyanate

in 25 mM sodium citrate with 0.1 M 2-mercaptoethanol
(pH = 7.0).

Cells were immediately vortexed and 0.5% Sarko-

syl was added to complete the cellular disruption.

This

mixture was layered over 4 ml of 5.7 M CsCl in 25 mM sodium
citrate

(pH * 5.0)

and centrifuged at 32K RPM in a Beckman

,
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SW-40 rotor for 18 h at 20°C.

The RNA pellet was resuspended

in sterile water and reprecipitated.

The final RNA pellet

was resuspended in TE7.5 and quantitated spectrophotometrically by A260.
Ten ug of RNA was heat-denatured in 50% formamide and 6%
formaldehyde and loaded onto a 1.2% agarose formaldehyde gel.
After electrophoresis in lx MOPS,

the 18S and 28S bands were

visualized by acridine orange staining and the RNA trans¬
ferred to nitrocellulose with 5x SSC.
The baked filters were prehybridized in a buffer con¬
taining 50% formamide and 10% dextran sulfate at 42°C for 2
to 12 hr and then hybridized in the same solution for ap¬
proximately 24 hr at 42°C.

Blots were rinsed in 2x SSC with

0.5% SDS at room temperature, washed for 15 min in 2x SSC
with 0.5% SDS at room temperature,
SSC with 0.1% SDS at 42°C,

washed for 20 min in lx

and finally washed for 30 min in

0.5x SSC with 0.1% SDS at 65°C.

The blots were exposed to

Kodak XRP film for 24 to 48 hours at -70°C.

CYTODOT ANALYSIS
Cytodot analysis was accomplished by a modification of a
published technique
analysis

(57)

(see Figure 1).

that was arrived at after systematic
Two x 10

6

cells were washed twice

in ice-cold PBS and resuspended in 45 ul of TE7.0 and 1000
units of RNAsin.

Five ul of 5% NP40 were added and the

mixture incubated on ice for 5 min.

Another 5 ul of 5% NP40

■
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FIGURE 1:
with NP40,
ods,

Cytodot probed with v-myc♦
RNasin,

Lane 2 cells treated

and Centrifugation as described in Meth¬

other lanes had the following changes.

inhibitors added;
RNAsin;
added;

4-7,10:
6-10:

same as 6,

3,5,7,9:

1,10:

no RNAse

vanadyl nucleoside analogs

replace

phenol/c’nloroform extraction of supernatant

proteinase K treatment of supernatant added;

but RNAse added at end.

11:

CYTODOT PROTOCOL DEVELOPMENT
I x I06

I
•

5 x I05

• • •

2.5x I05
I.2xl05
6.2x I04
3.1 x I04
1.5 xIO4

•

23456
• •

•

•

789
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II
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were added and the mixture was incubated on ice for a further
5 minutes.

The nuclei were collected by centrifugation and

50 ul of the resulting suspension were added to 30 ul of
20x SSC.

The RNA was denatured with 7% formaldahyde at 60°C

for 20 min and the amount of solution representing 1 x 10^
cells was placed on Gene-Screen with a Minifold blotting
apparatus.

Dilutions

(1:2) were made with 15x SSC.

The

filters were baked and blotted as above.

SOUTHERN ANALYSIS
DNA was isolated from cells by a phenol/chloroform me¬
thod and analyzed by Southern blotting

(56,58).

Briefly,

cells were collected by centrifugation, washed in ice-cold
PBS,

resuspended in TE8.0,

0.5 M EDTA,

0.5% Sarkosyl,

solution at 50°C.
peated phenol,

and lysed with 10 volumes of a
and 100 ug/ul proteinase K

The nucleic acids were extracted by re¬

phenol/chloroform,

and chloroform extrac¬

tions and the solution dialyzed against TE8.0.

RNA was

removed by treating the solution with DNAse-free RNAse fol¬
lowed by repeated phenol/chloroform extractions.
second dialysis against TE8.0,
reprecipitation,
A260.

After a

the DNA was concentrated by

and quantitated spectrophotometrically by

Agarose gel electrophoresis showed that all of the DNA

so isolated was greater than 23kb.
Approximately 12 ug of DNA were cut by restriction
enzymes

(56),

the fragments separated on a 1.2% agarose gel,

11

and then transferred to nitrocellulose.
hybridization,

Prehybridization,

and washing were as for the Northern analysis.

PROBES
For Southern blots,
Mark Carmen was used.
probe

(60,61)

cells

(62),

(59)

For Northern blots,

provided by Dr.
a murine c-myc

and a human N-ras probe isolated from HL-60

both of which were received from the American

Type Culture Collection,
from

a v-myc probe

were used.

Probes were isolated

coli using standard procedures

(56).
g

All probes were labeled to approximately 9 x 10
by an oligonucleotide labeling technique

(63).

Briefly,

denatured probe was incubated with oligonucleotides,
dGTP,

dTTP,

32

P-dCTP,

DNA synthetase.

cpm/ug

dATP,

and the Klenow fragment of bacterial

Free nucleotides were separated from the

labeled probe by passage over a G-50 column.

DENSITOMETRY
Radioautographs were densitometrically scanned using a
Zeineh soft laser scanning densitometer equipped with an
Apple computer which was used for data analyses.

CHEMICALS AND SOLUTIONS
All chemicals used were of the highest grade available
and supplied by standard laboratory suppliers.
were sterilized in an autoclave before use.

All solutions

In addition,

.
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glassware for RNA work was baked at 250°C for 4 hr prior to
use.
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RESULTS

CELL ISOLATION AND CHARACTERIZATION
Under the conditions employed parental HL-60 cells had a
doubling time of about 36 hours and plateaued after 3 doub¬
lings.

When treated with 1.2% DMSO or 1 uM RA,

their growth

was inhibited and they acquired a differentiated phenotype as
assayed by the ability to reduce NBT (Figure 2).
To create an HL-60 line resistant to DMSO induced dif¬
ferentiation,

parental HL-60 cells were continuously main¬

tained in medium with serially increasing concentrations of
DMSO until a culture resistant to 1.2% DMSO was created.
This was successful
cells grew well

in three instances.

in 1.2% DMSO

In each case the

(albeit somewhat more slowly

than the parental line) without showing any ability to
duce NBT.

However,

drug-free medium,
cause of the close

these

re¬

resistant lines died when placed in

indicating a dependency on DMSO (*).

Be¬

resemblance to the growth characteristics

of the parental line,

one of these

resistant lines,

termed

HL-60-DA, was selected for further study.
Figure 3 shows the growth and differentiation of
HL-60-DA cells in DMSO concentrations ranging from 1.2% to
2.2%.

The cells grew well

in 1.2% to 1.6% DMSO;

however,

they demonstrated up to 20% NBT positivity at this latter
concentration.

As the DMSO was further increased,

the cells

grew less well and demonstrated greater NBT positivity.

*This initial work was carried out by David Frank,

MD,

A

PhD.
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FIGURE 2:

HL-60 growth and differentiation

(inset).

tions and measurments are as described in Methods.
point

Condi¬
Each

represents a separate flask and is the average of at

least duplicate samples.

HL-60 GROWTH AND DIFFERENTIATION

CELLS/ML (xl O'6)

100

80
LU

>

b 60
a>

o
CL

fe40

2
I i_i_i_i_i_i_i

0

2

4

TIME (days)

6

4

TIME (days)

6

#

16

FIGURE 3:

HL-60-DA dose

response to DMSO.

Culture conditions

and measurments are as described in Methods.

The accompaning

tabular insert shows the percentage of cells capable of
reducing NBT on the last day of culture.

Cells treated with

2.2% DMSO were not assayed due to the large amount of cellu¬
lar debris.

CELLS/ML (xl0 6)
O

HL-60-DA DOSE RESPONSE

TIME (days)
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DMSO concentration of 2.2% was toxic,

as demonstrated by

cellular vacuolation and debris after 3 days in culture.
As mentioned above,

it has been reported that myc ex

pression decreases dramatically in parental HL-60 cells upon
DMSO induced differentiation

(34).

Therefore,

I assayed myc

RNA levels in HL-60-DA cells during exponential growth,
well as during plateau phase.

An RNA "dot blot"

as

showed that

myc expression in the mutant line was significantly lower
than in the uninduced parental line and was approximately as
low as in DMSO induced parental HL-60 cells
These studies,

(data not shown).

however, were complicated by the necessity of

continuously maintaining the mutant cell line in DMSO.
was impossible,

therefore,

to determine whether this decrease

was a DMSO-induced effect or a permanent alteration.
this reason,

It

For

I attempted to isolate a cell line that remained

resistant to DMSO induced differentiation but was not depen¬
dent on it for growth.
To this end,
free medium.

some HL-60-DA cells were placed in drug-

In contrast to earlier

results,

after two

passages a cell line developed that grew well both in the
presence and absence of DMSO.

This line,

DAl, was maintained in drug-free medium.

now termed HL-60Figure 4

shows the

growth and NBT positivity of HL-60-DA1 cells in 1.2% DMSO,
1 uM RA,

and in drug free medium.

in

This cell line grew

slightly better in the medium with DMSO than in the drug-free
medium,

but failed to differentiate in either case.

Surpri-

19

FIGURE 4:

Growth of HL-60-DA1 cells in presence of DMSO or RA

Culture conditions and measurements are as described in Meth¬
ods.

The accompaning tabular insert shows the percentage of

cells capable of

reducing NBT on the last day of culture.

CELLS/ML (xio’6)
o

HL-60-DA1 GROWTH

TIME (days)
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singly,

the cells also grew well,

and differentiated only

partially (30% NBT positivity) when exposed to RA.

Control

HL-60 cells cultured at the same time and induced with either
RA or

DMSO showed the expected growth inhibition and greater

than 75% NBT positivity at plateaued growth,

thus demonstra¬

ting that the assays were functioning properly.

Subsequent

experiments demonstrated that the growth of HL-60-DA1 cells
was inhibited and differentiation occurred, with the cells
expressing greater than 75% NBT positivity, when they were
placed in both 1.2% DMSO and luM RA (data not shown),

thus

proving that the resistance to differentiation was not abso¬
lute.
The HL-60-DA1 cells maintained their mutant phenotype
for approximately fifteen passages in drug-free medium and it
was initially felt that this was a stable mutant.
ately,

Unfortun¬

as the cells continued to be passaged in drug-free

media in preparation for measuring myc RNA expression,

it was

noted that they began to revert back to the parental pheno¬
type.

For this

reason,

some of the early passage HL-60-DA1

cells were removed from frozen storage and placed in medium
supplemented with 1.2% DMSO to maintain the selective pres¬
sure.

Unlike the parental line,

the

recovery of viable cells

from the frozen stock of HL-60-DA1 cells was extremely low
and estimated to be less than 1%.
A viable culture was eventually created and these cells,
now termed HL-60-DA2, were maintained in 1.2% DMSO until

•
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ready for study.

Figure 5 shows their initial growth and

differentiation.

Although qualitatively similar to the ori¬

ginal HL-60-DAl cells,

they do show some differences.

still grow well in drug free,

DMSO treated,

They

or RA treated

media,

but now show up to 50% NBT positivity with RA treat¬

ment.

In addition,

cells treated with both RA and DMSO also

developed only 50% NBT positivity,

although they did so more

rapidly than those treated with RA alone.

A control HL-60

culture grown and assayed at the same time once again res¬
ponded as usual.

To further characterize these cells,

Wright-Giemsa stained samples from the cultures were examined
for morphological changes

(Figure 6).

The cells in drug-free

or DMSO treated media both matured slightly from predomin¬
antly promyelocytes to approximately 50% myelocytes.

The

drug-free cells seemed to mature somewhat more extensively,
but this was not statistically significant

(p >

0.05 by X

2
I

analysis).

Cells treated with both RA and DMSO differen¬

tiated so that a majority of the cells
cytes or bands.

Unfortunately,

resembled metamyelo¬

the sample for the 8-day

treatment with RA was lost thereby making analyses difficult.
These findings confirmed the NBT results and correlated well
with them,

in so much as metamyelocytes are considered the

earliest cells capable of expressing NBT positivity.
Stock HL-60-DA2 cells were continuously maintained in
1.2% DMSO for two months,
the above results,

at which time the confirmation of

as well as the

results of the myc analysis

23

FIGURE 5:

HL-60-DA2 growth and differentiation.

Culture

conditions and measurements are as described in Methods.

CELLS/ML (xIO'6)

HL-60-DA2 GROWTH AND DIFFERENTIATION

TIME (days)
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FIGURE 6:

Morphological differentiation of HL-60-DA2 cells

Assay performed as described in Methods.

All

blinded,

and the

at least 200 cells were counted,

samples were
results

represent the average of at least duplicate measurements.
Error bars

represent + one standard deviation or

ever is greater.

5%, which

HL-60-DA2 MORPHOLOGY
CONTROL

m = promyelocytes
I

1.2% DMSO

E23 = myelocytes

I = metamyelocytes IM = hands
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discussed below, was attempted.

The experiment was repeated

in the exact manner as before except that the cells were
cultured in smaller flasks.

Figure 7 shows their growth and

NBT positivity and Figure 8 the morphological analysis.

It

is clear that the cellular characteristics had changed and
thus they are now termed HL-60-DA3 cells.

These cells grew

well even in the presence of both RA and DMSO and expressed a
maximum of 10% NBT positivity under those conditions.
phology confirmed these results for the drug-free,
treated,

and the RA treated cultures.

Mor¬

the DMSO

The cultures treated

with both RA and DMSO developed more metamyelocytes and bands
than would be predicted from the NBT test but still not as
many as the HL-60-DA2 cells

(see Figure 6).

Parental HL-60

cells cultured and tested at the same time and with the same
reagents once again behaved as expected.

ANALYSIS OF THE MYC ONCOGENE
RNA was isolated at various times from the cells des¬
cribed in Figures 5 and 6 and probed for the myc oncogene.
Since it has been shown that N-ras RNA levels do not change
with HL-60 differentiation

(19),

the blots were simultaneous¬

ly probed for this oncogene as a control.

Figure 9 shows the

Northern blots and Figure 10 the densitometric scanning re¬
sults.

All bands are consistent with previously reported

sizes for these RNA species

(34,62,64).

With a few minor
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FIGURE 7:

HL-60-DA3 growth and differentiation,

Culture

conditions and measurements were as described in Methods.

)
'6

CELLS/ML (xIO

HL-60-DA3 GROWTH AND DIFFERENTIATION

TIME (days)

30

FIGURE 8:

Morphological differentiation of HL-60-DA3 cells.

Analyses are as in Figure 6.

HL-60-DA3 MORPHOLOGY

CONTROL

1.2% DMSO

□
□
PERCENT

13

PERCENT

1 uM RA

1 uM RA + 1.2% DMSO

PROMYELOCYTE
MYELOCYTE
METAMYELOCYTE
BANDS
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FIGURE 9:

Northern analysis of total RNA isolated from HL-60-

DA2 cells and probed with human N-ras and mouse c-myc.
Twenty micrograms of total RNA were isolated,
hybridized as described in Methods.

separated,

and

Bands were labeled and

confirmed by independent hybridizations.

N-ras bands were

more clearly visualized on the original autoradiograph and on
overexposure of the film.

MYC AND N-RAS RNA EXPRESSION
HL-60

HL-60-DA2

Control

1.2% DMSO

Control

Id 3d 6d

Id 3d 6d

Id 4d lOd

-• •

HL-60-DA2
1.2% DMSO

I ^.M RA

Id 4d lOd

Id 4d 8d

1.2% DMSO + l/x M RA
Id 4d 7d
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FIGURE 10:
from

Densitometric measurements of Northern analysis

Figure 9.

N-ras bands could not be scanned because of

their low intensity.

DENSITY (arbitrary units)

MYC RNA EXPRESSION

TIME (days)
CONTROL
+1.2% DMSO
-*■ +1 uM RA
-o- +1 uM RA& 1.2% DMSO
-*■

TIME (days)
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exceptions attributable to loading variations,
of N-ras remained relatively constant.
ever,

varied dramatically.

the RNA levels

Myc RNA levels,

First of all,

how¬

the untreated par¬

ental HL-60 cells consistently expressed high levels of myc
which were dramatically reduced when the cells were induced
to differentiate with DMSO.

The 5 to 20-fold decrease in

myc expression is consistent with previously published
data

(19,34).

The untreated HL-60-DA2 cells showed even

higher levels of myc RNA expression than the untreated paren¬
tal line.

Given the difficulty of accurately scanning the

high density bands in these experiments,

it is not known if

the modest decline over time seen in Figure 10 is signifi¬
cant.

Treatment with DMSO,

differentiation,
RNA.

which in this line does not cause

once again caused a dramatic decrease in myc

Treatment with RA, which causes moderate differenti¬

ation,

induced similar changes.

Treatment with RA and DMSO,

which caused moderate differentiation at a faster

rate than

RA alone,

similar

produced a dramatic decline in myc RNA,

to

that seen in the differentiating parental line.
To confirm these
using a cytodot method

results,
(57).

I attempted to repeat them
Preliminary experiments showed

that this was a feasible technique

(see Methods).

This

method was chosen for its rapidity and convenience in ana¬
lyzing samples and time points.

In addition,

densitometric

scanning was easier than with the Northern blots.

The draw¬

backs include difficulty in controlling for nonspecific bin-

/
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ding of the probe and,
units/cell

since RNA levels are expressed in

rather than in units/ug of total RNA,

difficulty

in comparing the results to the earlier Northern blots.

I

attempted to circumvent the first by using the same stringent
washing conditions as for the Northern analysis.
difficulty,

however,

cannot be ameliorated,

argued that the amount of myc per cell
more important value.
described above,

The second

but it may be

is the physiologically

In addition to these drawbacks,

and as

the characteristics of the HL-60 mutant

changed in the interval between the experiments.
Despite these problems the
Figure 11
12 the

shows some of the

results were very similar.

representative blots and Figure

results from densitometric scanning.

It should be

first noted that the changes in myc RNA levels are not as
dramatic as with the Northern blots.

This finding is probab¬

ly due to the inherent high levels of nonspecific binding.
Nevertheless,

N-ras levels did not change with treatment or

over time in the parental line,

while a slight decline oc¬

curred over the course of the experiment in the mutant.
decline was consistent and equal
ments.

In addition,

This

for all of the four treat¬

it was observed that the density of the

N-ras dots in the mutant were higher than in the parental
line.

It is not known if this reflects a relatively higher

concentration of that RNA species within the cell or simply
an artifact.
As seen with the Northern blots,

myc RNA levels declined
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FIGURE 11:

Representative cytodots probed with human N-ras or

mouse c-myc.
screen,

One xlO^ cells were treated,

blotted onto gene-

and hybridized as described in Methods.

and probes used are indicated.

Dilutions
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FIGURE 12:

Densitometric measurements of cytodots

in Figure 11.
mately equal.

represented

N-ras and myc density scales are only approxi¬

DENSITY (arbitrary units)

MYC AND N-RAS RNA EXPRESSION

DENSITY (arbitrary units)

TIME (days)
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a
♦
■
♦
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significantly in HL-60 cells induced to differentiate with
either DMSO or HA.

The decrease was evident as early as 2

hours and completed by 8 hours in the DMSO treated cells and
by 24 hours in the RA treated ones.

The untreated HL 60-DA3

cells showed myc RNA levels that were consistantly twice
those of the untreated parental line.

When treated with

DMSO, which did not induce differentiation,

a dramatic early

decrease in myc expression occurred which returned to inter¬
mediate levels afte 1 day.

The change in myc RNA expression

in RA treated HL-60-DA3 cells,
entiate,

that also did not differ¬

was somewhat different than in the results with the

HL-60-DA2 cells.

Myc RNA levels stayed high for several days

and then decreased to intermediate levels when the plateau
phase was reached.

When HL-60-DA3 cells were treated with

both RA and DMSO, which induced only minimal differentiation,
the changes in myc were similar to those noted with the
HL-60-DA2 cells.
a slight
similar

Thus,

an early dramatic drop occurred with

reaccumulation at the time of plateau growth.

A

reaccumulation at the plateau phase also occurred in

the DMSO treated cells.
To analyze the myc genomic organization,
mutant line was analyzed by Southern blotting.

DNA of

the

Figure 13

shows no difference between the HL-60 and the HL-60-DA2 cells
indicating that no gross rearrangement or significant change
in the amplification of the myc gene occurred in the mutant
line as compared to the parental

line.

All bands were in
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FIGURE 13:

Southern analysis of the myc genome

HL-60-DA2 cells.
ted,

in HL-60 and

Twelve micrograms of total DNA were diges¬

separated and hybridized as described in Methods.

Res¬

triction enzymes and molecular weight markers are as indi¬
cated.
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their previously reported locations

(44,59,65,66),

except for

the 4.0 kB EcoRl band and the high molecular weight band seen
with BamHI digestion.
plete digestion

The latter can be attributed to incom¬

(data not shown).
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DISCUSSION

A DMSO Selected Differentiation Mutant Exhibits Cross
Resistance to Retinoic Acid
An HL-60 mutant line that is resistant to DMSO and RA
induced differentiation was developed and characterized.
This line was then analysed for myc RNA expression in res¬
ponse to these agents.

Although the line was created by

selective pressure from constant DMSO exposure,
to also be

it was found

resistant to RA induced differentiation,

previously reported for another DMSO resistant line

a finding
(51).

That the cells are indeed a differentiation mutant and not a
mutant in the ability to respond to the NBT assay was shown
by morphological analysis.
The changing characteristics of this line are note¬
worthy.

First, when no selective pressure was maintained the

line reverted back to the parental phenotype; whereas,

when

the selective pressure was continuously maintained the line
became even more cross-resistant to the RA.

This in itself

is not too surprising in so far as parental cells usually
have a growth advantage under the standard culture conditions
and will thus eventually dominate the culture.
with the greatest resistance,

on the other hand,

nate when selection pressure is maintained.

The mutants
will domi¬

It is not im¬

mediately clear whether the phenomenon is due to inducible
genetic material

in a clonal line

(such as homogeneously

47

staining chromosomal regions or double minute chromosomes)
to a heterogeneous cell population.

or

It has been shown that

the HL-60 line has a very aberrant karyotype that does con¬
tain double minutes,
plified genes

homogeneously staining regions,

(2,35,26,67,68).

and am¬

Genetic amplification that

would then be lost in the abscence of selective pressure is
thereby easily envisioned

(69).

However,

given the large

numbers of cells used and the previously reported karyotypic
heterogeneity of the parental HL-60 cell

line

(2,67,68),

it

must be assumed that the mutant line is also a nonclonal and
heterogeneous cell population.
With this heterogeneity and the lack of knowledge

re¬

garding the mechanism of differentiation produced by both
DMSO and RA,

it is difficult to dissect the exact mechanism

by which the cells express
However,

resistance to differentiation.

given the vastly different chemical

structures and

concentrations at which DMSO and RA are effective,

it is not

likely that their differentiation induction pathways are
exactly the same.

In fact,

it has been postulated that RA

exerts its effects through a specific RA binding protein
(70,71), while DMSO may exert its effects through a nonspeci¬
fic membrane interaction

(72).

In addition,

isolate of the mutant line described here

the original

responded partially

to RA and responded well to combined treatment,

thereby

giving further support to the possible existence of multiple
differentiation mechanisms.

Nevertheless,

because the final
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outcome of all differentiation inductions are very similar,
the biochemical events produced by each of these mediators
must eventually intersect.

Thus,

since the line described

here eventually became resistant to both agents,

the mutation

almost certainly involves one of these intersecting events.

The Proliferating,

Undifferentiated Phenotype Does Not

Require Elevated myc Expression
Once the

resistant line was established,

I attempted to

use it to probe for the role of the myc oncogene in differen¬
tiation.

The presumed heterogeneous cell cultures and the

changing phenotype made
impossible.

rigorous analysis of the measurements

The changes in both myc and N-ras RNA expres¬

sion in the parental line is well within the
vious

reports

technique,
in other

(19,34).

The changes seen with the cytodot

as mentioned before,

reports but,

realms of pre¬

are not quite as dramatic as

once again,

this was attributed to the

high nonspecific signal seen with this technique.

Also,

kinetics of the decrease in myc were somewhat more

rapid than

in a previously published report
are unclear,

but careful

(19).

The

the

reasons for this

reading and analysis of published

HL-60 growth curves and response to standard differentiation
inducers from different laboratories shows that significant
variation occurs despite comparable culture conditions.
Thus,

the different kinetics of the decline in myc RNA may

simply be an example of divergent cell line evolution.
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The results with the myc oncogene in the mutant HL-60
line are at first glance confusing.
ing conclusions can be made.

However,

some interest¬

The Northern gel of the

HL-60-DA2 RNA clearly shows a marked decrease in myc RNA
levels with both DMSO and RA treatment that is proportionally
as great as that seen in the parental line when compared to
the untreated control.

Yet there is no or only limited

differentiation.

in this case,

Thus,

a decrease in myc RNA

expression was not sufficient for differentiation to occur.
Or looking at it in another way,

high myc levels are not

necessary to maintain the undifferentiated,
phenotype.

proliferating,

It may be argued that it is not the

relative

amount of myc in a cell that is important but the absolute
amount.

The Northern blots leave this question open because

myc RNA expression in both the RA and the DMSO treated cells,
despite being relatively less than the untreated control,
still greater than the differentiating parental line.

are

The

myc RNA levels in the mutant cells treated with both RA and
DMSO were decreased to the levels seen with DMSO treated
parental cells,

but they differentiate relatively well also.

The cytodot analysis,

however,

showed that HL-60-DA3

cells treated with both RA and DMSO have myc RNA levels that
are at least as low as that seen in differentiating parental
cells.

In this case,

limited extent.

Thus,

though,

they only differentiate to a

it seems that even an absolute decline

in myc RNA levels is not sufficient to cause differentiation

'
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in this line.

The cytodot methodology also confirms the

consistantly high constant myc RNA levels in the untreated
mutant cells.

In addition,

the cytodot analysis corroborated

the decline in myc RNA, without cellular differentiation,
that occurs with DMSO treatment.

The very early decline in

myc with subsequent reaccumulation is reminiscent of the
changes seen in differentiating Friend leukemia cells

(39).

One report also claims elevated myc expression at 24-48 h in
differentiating HL-60 cells
for,

(73).

Since it was not looked

it is not known if a similar biphasic change occurred in

the cells used for the Northern blots.

The high myc RNA

levels seen with RA treatment of the HL-60-DA3 cells as well
as the

rise in myc RNA levels seen in the DMSO and in the RA

plus DMSO treated cells at the plateau phase of growth was
not consistent with earlier results and is incompletely un¬
de r stood.
Finally,

when attempting to define the importance of a

putative mediator of a pathway,

it is the function of the

protein that is the physiologically important variable.

Al¬

though myc protein and RNA levels have been correlated
(74,80),

until a good assay for myc protein function is

developed,

this limitation will

remain.

For now then,

will assume that a declining myc RNA level

we

reflects a decline

in the level and function of the myc protein.
In general myc RNA levels decline dramatically with HL60 differentiation

(19,34,41),

as well as with the

differen-

/
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tiation of several other cell lines

(38,40).

Also,

recent

work shows that constitutive expression of myc inhibits dif¬
ferentiation in mouse erythroleukemia cells
ditionally,

(44-46).

Ad¬

the kinetics of the decline in myc RNA parallels

the kinetics of the decline in the clonability and NBT
positivity of HL-60 cells but not the kinetics of thymidine
incorporation into DNA upon the induction of differentiation
(19).

Thus,

the data suggest that a decline in myc expres¬

sion is necessary for differentiation.
However,

there are many experimental

systems in which

increased myc RNA levels are related to the entrance of the
cells into a proliferative state

(74-83).

Thus,

it seems

that increased myc expression is associated with the proli¬
ferative state,
replication

and in fact may be directly involved in DNA

(84).

Another way of looking at the decrease

myc levels seen with differentiation,

therefore,

in

is that it

may simply be a reflection of the concomitant loss of prolif¬
erative capacity.

Although elevated myc levels are insuf¬

ficient to induce the
differentiated cells

replicative mode in some quiescent or
(82),

high myc levels could be suf¬

ficient to maintain the undifferentiated,
phenotype

(44-47).

In this scenario,

proliferating

one could postulate

that obligatory elevated myc expression occurs in all pro¬
liferating cells.
all tumor cells
embryo

(86),

Although this is certainly not true for

(23,85),

or even in all cells of a developing

there has been little direct evidence for the
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maintenance of the proliferating, undifferentiated phenotype
in the face of declining levels of myc RNA.
This study is the first to describe such a pattern.
That is,

a decline in myc expression is not correlated with

either the differentiated phenotype or the inhibition of
growth in the HL-60 differentiation mutant described here.
If the decline in myc is seen as mechanistically an important
step in the maturation process,

the obvious conclusion is

that a decrease in the expression of myc is not sufficient
for differentiation or,

alternatively,

the lesion in the

differentiation pathway of this mutant is distal to the point
at which a decline in myc RNA is initiated.
hand,

as suggested above,

On the other

myc expression can be seen as

mechanistically important in maintaining the proliferating,
undifferentiated phenotype.

In that case,

despite other

studies which have shown that high myc RNA expression is
sufficient for maintaining the undifferentiated,
ting state

(44-47),

prolifera¬

the conclusion of this study must be that

it is not always necessary.

NOTE ADDED IN PROOF:
Since writing this, Ely et al (Cancer
Res. 47, ?59~5-4600 ) have described a HL-60 mutant partially
resistant to phorbol dibutyrate induced monocytic differen¬
tiation in which myc expression initially declines drama¬
tically but then reaccumalates at 15 to 30 hours postinduc¬
tion.

■
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